scorecardresearch
Add as a preferred source on Google
Saturday, January 3, 2026
TopicCDSCO

Topic: CDSCO

Why apex ophthalmologists’ body wants to review new eye drops designed to replace reading glasses

All India Ophthalmological Society has set up expert group to review PresVu & develop guidelines on side-effects, keeping in mind 'potential inappropriate marketing, indiscriminate use'.

34 more fixed dose combination drugs likely to be banned, apex regulator says after big crackdown

A total of 344 such medicines were banned in 2018, and another 156, used for common conditions such as fever, allergies, hypertension, colds etc, earlier this month.

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Drug regulator’s plan to bring all nicotine replacement therapies under prescription gets ICMR nod

Doctors & experts are divided on the move's efficacy. Some believe this could help ensure responsible use, while others feel it could reduce access for those benefiting from it.

Drug regulator CDSCO asks all medical device makers to ‘self-report adverse events’ to mitigate risks

CDSCO says Centre’s programme to identify such risks has been in place since 2015, but till now only hospitals designated as monitoring centres would report such events on voluntary basis.

Central regulator to now give NOC for export of new, unapproved medicines after safety concerns

India’s exports of pharmaceuticals during 2022-23 was valued at $25.4 billion with a growth of almost 3.25 percent over the previous financial year, according to Pharmexcil.

Drug regulator tightens sampling norms to test quality of medicines & cosmetics reaching market

CDSCO last week notified streamlined guidelines on sampling, conceded that at present sampled drugs are mostly from big brands and urban areas. 

After prohibiting popular FDC for kids under 4, drug regulator scrutinises other cold & cough remedies

Following December notice prohibiting combination of chlorpheniramine maleate & phenylephrine hydrochloride, CDSCO has ‘decided to rope in paediatricians to review other permitted FDCs’.

Indian pharma firms now liable to recall defective drugs as Modi govt notifies new norms

Under revised good manufacturing practices (GMP) norms, pharma companies will be required to assume onus for quality of drugs to ensure they do not place patients at risk.

Global pharma majors pitch for faster approval of innovative drugs in India but CDSCO remains cautious

Organisation of Pharmaceutical Producers of India seeks nod for drugs to be marketed at same time as US, Europe. But regulator rarely permits a drug launch without local clinical trials.

On Camera

Savitribai Phule made space for radical women misfits. She pioneered Satyashodhak modernity

The distinctiveness of her writing is evident in her compositions—women, shudras, and atishudras are at the center. Her poetry challenges the aesthetics of 'modern' Marathi literature.

India’s urban co-op banks are turning the page—crisis to cautious revival, one metric at a time

With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.

Greece looking at TATA’s WhAP infantry combat vehicle for army procurement

If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.

A year-end Mea Culpa in National Interest—The Army-Islam combo doesn’t kill democracy

Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.